New Patent Granted for Prostate Cancer Drug Masitinib

Updated at: June 18, 2026 at 02:01 AM

A significant breakthrough in oncology has emerged as AB Science SA secured a U.S. patent for its lead compound, masitinib, targeting metastatic castrate-resistant prostate cancer (mCRPC).

nounbreakthrough

nounoncology

verbsecure

nounpatent

nounmasitinib

adjectivemetastatic

This patent, valid until 2042, marks a pivotal moment for a field that has seen no new combination therapies for nearly two decades.

nounpatent

adjectivepivotal

Masitinib works as a protein kinase inhibitor, intended to be used alongside docetaxel.

nouninhibitor

What sets this treatment apart is its commitment to precision medicine.

nounprecision

Clinical data from the Phase 3 AB12003 study showed a 21% reduction in disease progression risk for patients with ALP levels at or below 250 IU/L.

nounreduction

The long-term patent protection provides the stability needed for large-scale clinical trials, signaling a hopeful shift toward personalized, biomarker-driven cancer care.

nounpatent

🎉

End of article

You read 6 focus sentences.

Challenge Mode

Comprehension Questions

What is the primary function of masitinib in the context of mCRPC treatment?

It acts as a radioactive isotope to kill cancer cells.

It is a protein kinase inhibitor used as a combination therapy.

It serves as a hormonal therapy to block testosterone production.

Reveal Answer

✓

Correct Choice

It is a protein kinase inhibitor used as a combination therapy.

Why is the use of the biomarker alkaline phosphatase (ALP) significant?

It completely replaces the need for chemotherapy.

It helps identify patients who will most likely benefit from the therapy.

It increases the cost of treatment for the patient.

Reveal Answer

✓

Correct Choice

It helps identify patients who will most likely benefit from the therapy.

How long does the newly granted U.S. patent protect masitinib?

Until 2030.

Until 2050.

Until May 2042.

Reveal Answer

✓

Correct Choice

Until May 2042.

What did the Phase 3 AB12003 study demonstrate regarding patient outcomes?

A 21% reduction in the risk of disease progression for specific patients.

A 50% increase in patient mortality rates.

No significant difference compared to traditional chemotherapy.

Reveal Answer

✓

Correct Choice

A 21% reduction in the risk of disease progression for specific patients.

What is the goal of the upcoming confirmatory Phase 3 trial, AB22007?

To definitively confirm the safety and efficacy of the masitinib-docetaxel combination.

To prove that masitinib can be used without docetaxel.

To test the drug on patients with early-stage lung cancer.

Reveal Answer

✓

Correct Choice

To definitively confirm the safety and efficacy of the masitinib-docetaxel combination.

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.

App Store Google Play